Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity
- PMID: 2402017
- DOI: 10.1093/jnci/82.19.1562
Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity
Abstract
Illudins are potent natural products derived from Omphalotus illudens and related fungi. The chemical structure of illudins differs from that of other conventional chemotherapeutic agents. While illudins are toxic to most tumor cells after prolonged exposure (greater than or equal to 48 hr), with shorter exposure times (less than or equal to 2 hr), they show selective toxicity for human myelocytic leukemia and epidermoid, lung, ovarian, and breast carcinoma cells of various species of origin. The apparent histologic specificity of illudin S toxicity is based on an energy-dependent transport mechanism present in sensitive cells, but absent in cells relatively resistant to illudin S. For human myeloid leukemia HL60 cells, the Michaelis constant was 4.2 microM and the maximum velocity was 12.2 pmol/minute per 10 million cells or 730 pmol/hour per 10 million cells. The energy-dependent transport mechanism was detected in other mammalian tumor cells.
Similar articles
-
Preclinical evaluation of illudins as anticancer agents.Cancer Res. 1987 Jun 15;47(12):3186-9. Cancer Res. 1987. PMID: 3472654
-
On the mechanism of toxicity of illudins: the role of glutathione.Chem Res Toxicol. 1990 Nov-Dec;3(6):574-9. doi: 10.1021/tx00018a013. Chem Res Toxicol. 1990. PMID: 2103329
-
NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.Clin Cancer Res. 2004 Feb 15;10(4):1492-9. doi: 10.1158/1078-0432.ccr-03-0162. Clin Cancer Res. 2004. PMID: 14977853
-
Irofulven (MGI Pharma).Curr Opin Investig Drugs. 2002 Oct;3(10):1517-26. Curr Opin Investig Drugs. 2002. PMID: 12431030 Review.
-
Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.Bioorg Med Chem. 1999 May;7(5):881-6. doi: 10.1016/s0968-0896(99)00016-4. Bioorg Med Chem. 1999. PMID: 10400341 Review.
Cited by
-
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.Invest New Drugs. 2001;19(1):13-20. doi: 10.1023/a:1006432012394. Invest New Drugs. 2001. PMID: 11291829 Clinical Trial.
-
Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.Invest New Drugs. 2001;19(4):283-91. doi: 10.1023/a:1010601524630. Invest New Drugs. 2001. PMID: 11561687
-
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.Invest New Drugs. 2006 Jul;24(4):311-9. doi: 10.1007/s10637-005-5055-6. Invest New Drugs. 2006. PMID: 16683074 Clinical Trial.
-
Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent.J Pharmacol Exp Ther. 2012 Nov;343(2):426-33. doi: 10.1124/jpet.112.195768. Epub 2012 Aug 15. J Pharmacol Exp Ther. 2012. PMID: 22895897 Free PMC article.
-
Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.Invest New Drugs. 1996;14(2):161-7. doi: 10.1007/BF00210787. Invest New Drugs. 1996. PMID: 8913837
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources